Teacher Retirement System of Texas Acquires 2,994 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Teacher Retirement System of Texas boosted its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 18.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,083 shares of the biopharmaceutical company’s stock after buying an additional 2,994 shares during the period. Teacher Retirement System of Texas’ holdings in Xenon Pharmaceuticals were worth $748,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of XENE. Blue Trust Inc. lifted its holdings in shares of Xenon Pharmaceuticals by 140.3% in the fourth quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company’s stock worth $95,000 after buying an additional 1,414 shares in the last quarter. Avior Wealth Management LLC purchased a new stake in Xenon Pharmaceuticals in the 4th quarter worth approximately $101,000. KBC Group NV boosted its holdings in Xenon Pharmaceuticals by 39.8% in the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 780 shares during the period. HighMark Wealth Management LLC grew its position in shares of Xenon Pharmaceuticals by 22.0% during the 4th quarter. HighMark Wealth Management LLC now owns 6,100 shares of the biopharmaceutical company’s stock valued at $239,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Vestcor Inc bought a new position in shares of Xenon Pharmaceuticals in the third quarter worth $327,000. Institutional investors own 95.45% of the company’s stock.

Analysts Set New Price Targets

XENE has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft assumed coverage on Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They set a “buy” rating and a $67.00 price objective for the company. William Blair reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. HC Wainwright restated a “buy” rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. StockNews.com upgraded shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Royal Bank of Canada reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $57.38.

Xenon Pharmaceuticals Stock Performance

XENE stock opened at $34.26 on Monday. The company has a market capitalization of $2.62 billion, a PE ratio of -12.15 and a beta of 1.26. Xenon Pharmaceuticals Inc. has a one year low of $33.27 and a one year high of $46.00. The company’s 50 day moving average price is $37.72 and its two-hundred day moving average price is $39.74.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.05. On average, research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Insider Transactions at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 22,468 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $40.20, for a total value of $903,213.60. Following the transaction, the chief executive officer now owns 31,302 shares in the company, valued at approximately $1,258,340.40. This trade represents a 41.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.52% of the company’s stock.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.